Binimetinib/Encorafenib Combination Effective in BRAF-Mutant Melanoma
May 17th 2017Treatment with the combination of the MEK inhibitor binimetinib and the BRAF inhibitor encorafenib resulted in a superior progression-free survival for patients with advanced, unresectable BRAF-mutated melanoma compared with treatment with encorafenib alone.
Survival in MDS Equivalent With Reduced-Intensity Conditioning
May 9th 2017Patients with myelodysplastic syndrome undergoing a reduced–intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients who underwent myeloablative conditioning.
Tailored Prostate Cancer Screening May Be Warranted for Black Men
April 27th 2017The higher prostate cancer death rates seen among black men in the United States may be due to a higher incidence of preclinical disease and higher risk of metastatic progression, suggesting that different screening policies could benefit this population.